Results 51 to 60 of about 2,796 (165)
Frontiers in NeurologyHigh-grade gliomas (HGG) such as glioblastoma are the most aggressive primary malignancies of the central nervous system. The median overall survival of glioblastoma is <15 months despite treatment with surgery, radiotherapy, and chemotherapy ...
Zhihong Qian +4 more
doaj +1 more source
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
British Journal of Pharmacology, EarlyView.This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source
Assessment and development of adenovirus type 11 for cancer therapy [PDF]
, 2010 PhDThe efficacy of oncolytic virotherapy is influenced by the interactions between the tumour, virus and host immunity. The first generation of oncolytic adenoviruses, based on serotype 5 (Ad5), has achieved limited success in clinical trials.
Wong, Han Hsi
core
Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma
Cancer Treatment and Research Communications, 2021 The treatment focus for multiple myeloma (MM) has recently pivoted towards immune modulating strategies, with T-cell redirection therapies currently at the forefront of drug development.
Joselle Cook, MD +4 more
doaj +1 more source
Integrated Engineering of CAR‐T Cells for Solid Tumours
Cell Proliferation, EarlyView.Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang +5 more
wiley +1 more source
Oncolytic Virotherapy for Hematological Malignancies [PDF]
Advances in Virology, 2012 Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can be used. However, in the setting of autologous HCT, relapse due to contamination of the autograft with cancer ...
Swarna Bais +4 more
openaire +3 more sources
Regulation of adenovirus replication by miR-199 confers a selective oncolytic activity in hepatocellular carcinoma [PDF]
, 2012 Oncolytic virotherapy represents a growing field of experimental cancer therapy. For safe and effective virotherapy, restricted tissue expression and replication of the virus is desirable.
Khalid Elamin Elhag, Baha Eldin
core
Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy
MedComm, Volume 7, Issue 8, August 2026.Barrier‐defined strategies for cold‐to‐hot tumor conversion. Cold tumors include immune‐desert and immune‐excluded states marked by poor antigen visibility, limited T‐cell priming, stromal or vascular exclusion, metabolic stress and suppressive immune programs.
Xiao Ge +5 more
wiley +1 more source
The role of autophagy in neoplastic cell response to oncolytic viruses [PDF]
, 2009 Oncolytic conditionally replicating adenoviruses (CRAds) are viral mutants able to selectively replicate in tumour cells. CRAds are considered a promising platform for cancer therapy. dl922-947, bearing a mutation in E1A gene and AdΔΔ, carrying mutations
Botta, Ginevra
core
Molecular Therapy: Oncolytics, 2019 As a clinical setting in which novel treatment options are urgently needed, hepatocellular carcinoma (HCC) exhibits intriguing opportunities for oncolytic virotherapy.
Yong Luo +11 more
doaj +1 more source